Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan.

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Journal of Clinical Oncology

• Publication date

  2004-04-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.1200/JCO.2004.07.173PMID 15007088
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

  2004cited by this paper
• Evidence for a gene influencing serum bilirubin on chromosome 2q telomere: a genomewide scan in the Framingham study.

  2003cited by this paper
• Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer.

  2003cited by this paper
• UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity

  2002cited by this paper
• Irinotecan dosing: does the CPT in CPT-11 stand for "Can't Predict Toxicity"?

  2002cited by this paper
• Haplotype structure of the UDP-glucuronosyltransferase 1A1 promoter in different ethnic groups.

  2002cited by this paper
• A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients.

  2001cited by this paper
• Genotyping of two mutations in the HFE gene using single-base extension and high-performance liquid chromatography.

  2001cited by this paper
• Irinotecan in the treatment of colorectal cancer: clinical overview.

  2001cited by this paper
• Association of plasma bilirubin with coronary heart disease and segregation of bilirubin as a major gene trait: the NHLBI family heart study.

  2001cited by this paper
• Phase I dose-finding and pharmacokinetic trial of irinotecan (CPT-11) administered every two weeks.

  2001cited by this paper
• Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.

  2000cited by this paper
• Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis.

  2000cited by this paper
• Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group.

  2000cited by this paper
• Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer.

  2000cited by this paper
• Donor liver uridine diphosphate (UDP)-glucuronosyltransferase-1A1 deficiency causing Gilbert's syndrome in liver transplant recipients.

  2000cited by this paper
• Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer.

  1998cited by this paper
• Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes.

  1998cited by this paper
• Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: a balanced polymorphism for regulation of bilirubin metabolism?

  1998cited by this paper
• Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer.

  1998cited by this paper
• Pharmacokinetic and pharmacodynamic evaluation of the topoisomerase inhibitor irinotecan in cancer patients.

  1997cited by this paper
• Evidence for a major gene elevating serum bilirubin concentration in Utah pedigrees.

  1996cited by this paper
• Genetic variation in bilirubin UDP-glucuronosyltransferase gene promoter and Gilbert's syndrome

  1996cited by this paper
• The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome.

  1995cited by this paper
• Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea.

  1994cited by this paper
• Bilirubin UDP-glucuronosyltransferase 1 is the only relevant bilirubin glucuronidating isoform in man.

  1994cited by this paper
• Phase I and pharmacokinetic trial of weekly CPT-11.

  1993cited by this paper
• Phase I study of weekly intravenous infusions of CPT-11, a new derivative of camptothecin, in the treatment of advanced non-small-cell lung cancer.

  1991cited by this paper
• Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11.

  1991cited by this paper

• Survival of patients with colorectal or pancreatic cancer who received UGT1A1 genotype-guided dosing of irinotecan in the Netherlands (2017-2024): a retrospective, multicentre cohort study.

  2026cites this paper
• Inhibition of UDP-glucuronosyltransferases by Fedratinib, Implying a High Risk of Drug-drug Interactions.

  2026cites this paper
• Dose-Limiting Toxicities and the Maximum Tolerated Dose of Irinotecan Based on UGT1A1 Genotypes: A Systematic Review

  2025cites this paper
• Multifunctional delivery strategies and nanoplatforms of SN-38 in cancer therapeutics.

  2025cites this paper
• Toxicities and management strategies of emerging antibody–drug conjugates in breast cancer

  2025cites this paper
• Pharmacogenomic and Clinical Predictors of Deferasirox Response in Transfusion‐Dependent Thalassemia Identified Using Whole‐Genome Sequencing

  2025cites this paper
• Clinical Experience With Preventing Chemotherapy-Induced Neutropenia in Breast Cancer Patients With Different Timings of Pegylated Granulocyte Colony-Stimulating Factor (PEG-G-CSF) Injection: A Case Series

  2025cites this paper
• UGT1A1 polymorphisms and metabolic phenotypes in indigenous peoples from the Brazilian Amazon

  2025cites this paper
• Pharmacogenomic Analysis of Genetic Variability in Drug Metabolizing Enzymes-Implications for Personalized Medicine

  2025cites this paper
• Unraveling the pharmaceutical excipient-drug interactions: The effects of polyethylene glycol copolymers on drug metabolism and transport systems.

  2025cites this paper
• A Forty-Three-Year-Old Male With Penile and Cavernous Metastases From Rectal Cancer

  2025cites this paper
• Managing Irinotecan-Induced Diarrhea: A Comprehensive Review of Therapeutic Interventions in Cancer Treatment

  2025influential citation
• Neoadjuvant chemoradiotherapy with capecitabine and irinotecan guided by UGT1A1 status in patients with locally advanced rectal cancer: 5‐year update of the CinClare trial

  2025cites this paper
• Targeted drug monitoring in oncology for personalized treatment with use of next generation analytics

  2025cites this paper
• Model‐Based Prediction of Irinotecan‐Induced Grade 4 Neutropenia in Cancer Patients: Influence of Incorporating Germline Genetic Factors in the Model

  2024cites this paper
• Canadian Expert Recommendations on Safety Overview and Toxicity Management Strategies for Sacituzumab Govitecan Based on Use in Metastatic Triple-Negative Breast Cancer

  2024cites this paper
• UGT1A1 Testing in Breast Cancer: should it become routine practice in patients treated with antibody-drug conjugates?

  2024cites this paper
• Pharmacogenomics and Personalized Medicine

  2024cites this paper
• Cetuximab plus FOLFOXIRI versus cetuximab plus FOLFOX as conversion regimen in RAS/BRAF wild-type patients with initially unresectable colorectal liver metastases (TRICE trial): A randomized controlled trial

  2024cites this paper
• Safety and efficacy of liposomal irinotecan as the second-line treatment for advanced pancreatic cancer: A systematic review and meta-analysis.

  2024cites this paper
• Targeting PARP-1 and DNA Damage Response Defects in Colorectal Cancer Chemotherapy with Established and Novel PARP Inhibitors

  2024cites this paper
• Rapid detection of the irinotecan-related UGT1A1 & 5-fluorouracil related DPYD polymorphism by asymmetric polymerase chain reaction melting curve analysis.

  2024cites this paper
• Machine learning in onco-pharmacogenomics: a path to precision medicine with many challenges

  2024cites this paper
• Prediction for oxaliplatin‐induced liver injury using patient‐derived liver organoids

  2024cites this paper
• Combination of irinotecan silicasome nanoparticles with radiation therapy sensitizes immunotherapy by modulating the activation of the cGAS/STING pathway for colorectal cancer

  2023cites this paper
• The expanding role of gene-based prescribing for phase II drug-metabolizing enzymes

  2023cites this paper
• Heterogeneity in precision oncology

  2023cites this paper
• Current Role of Topoisomerase I Inhibitors for the Treatment of Mesenchymal Malignancies and Their Potential Future Use as Payload of Sarcoma-Specific Antibody-Drug Conjugates

  2023cites this paper
• FOLFIRINOX in Pancreatic Cancer: Risk Factors for Febrile Neutropenia and Severe Neutropenia — Nationwide Study Analysis

  2023cites this paper
• Racial differences in longitudinal toxicities of anticancer agents in early phase cancer clinical trials

  2023cites this paper
• Predictive Value of ABCC2 and UGT1A1 Polymorphisms on Irinotecan-Related Toxicities in Patients with Cancer

  2023cites this paper
• UGT1A1 genotype-guided dosing of irinotecan: time to prioritize patient safety.

  2023cites this paper
• Incidence and non-genetic risk factors of irinotecan-induced severe neutropenia in Chinese adult inpatients

  2023cites this paper
• Genotyping of UGT1A1*80 as an Alternative to UGT1A1*28 Genotyping in Spain

  2022cites this paper
• Use of Personalized Biomarkers in Metastatic Colorectal Cancer and the Impact of AI

  2022cites this paper
• The UGT1A9*22 genotype identifies a high-risk group for irinotecan toxicity among gastric cancer patients

  2022cites this paper
• A dose regimen-finding study to evaluate the safety, tolerability, pharmacokinetics, and activity of oratecan in subjects with advanced malignancies

  2022cites this paper
• Incidence of and risk factors for severe neutropenia during treatment with the modified FOLFIRINOX therapy in patients with advanced pancreatic cancer

  2022cites this paper
• Role of Ginseng, Quercetin, and Tea in Enhancing Chemotherapeutic Efficacy of Colorectal Cancer

  2022cites this paper
• Prediction of Drug–Drug Interaction Between Dabrafenib and Irinotecan via UGT1A1-Mediated Glucuronidation

  2022cites this paper
• The influence of UGT1A1 polymorphisms on modified FOLFIRINOX dose in double-variant-type patients with advanced pancreatic cancer

  2022cites this paper
• Evaluation of UGT1A1 and CYP3A Genotyping and Single-Point Irinotecan and Metabolite Concentrations as Predictors of the Occurrence of Adverse Events in Cancer Treatment

  2022cites this paper
• A phase I evaluation of the effect of curcumin on dose‐limiting toxicity and pharmacokinetics of irinotecan in participants with solid tumors

  2022cites this paper
• Defining Clinical Utility of Germline Indicators of Toxicity Risk: A Perspective

  2022cites this paper
• Impact of UGT1A1 Polymorphisms on Febrile Neutropenia in Pancreatic Cancer Patients Receiving FOLFIRINOX: A Single-Center Cohort Study

  2022cites this paper
• Modern developments in germline pharmacogenomics for oncology prescribing

  2022cites this paper
• Drug‐Drug Interactions and Disease Status Are Associated With Irinotecan‐Induced Hepatotoxicity: A Cross‐Sectional Study in Shanghai

  2022cites this paper
• Pharmacogenetics of Drugs Used in the Treatment of Cancers

  2022cites this paper
• UGT1A1 genotype-guided dosing of irinotecan: A prospective safety and cost analysis in poor metaboliser patients.

  2022cites this paper
• Pharmacogenomics Driving Precision Cancer Medicine

  2022cites this paper
• A Review of Potential Role of Capsule Endoscopy in the Work-Up for Chemotherapy-Induced Diarrhea

  2022cites this paper
• Dutch pharmacogenetics working group (DPWG) guideline for the gene–drug interaction between UGT1A1 and irinotecan

  2022cites this paper
• Clinically actionable genotypes for anticancer prescribing among >1500 patients with pharmacogenomic testing

  2022cites this paper
• Postmortem study of organ-specific toxicity in glioblastoma patients treated with a combination of temozolomide, irinotecan and bevacizumab

  2022cites this paper
• Phase Ib SEASTAR Study: Combining Rucaparib and Sacituzumab Govitecan in Patients With Cancer With or Without Mutations in Homologous Recombination Repair Genes

  2022cites this paper
• Pharmacogenomic mechanisms of drug toxicity

  2022cites this paper
• Model‐Based Prediction of Irinotecan‐Induced Grade 4 Neutropenia in Advanced Cancer Patients: Influence of Demographic and Clinical Factors

  2022cites this paper
• Cost-Effectiveness of Pharmacogenomics-Guided Prescribing to Prevent Gene-Drug-Related Deaths: A Decision-Analytic Model

  2022cites this paper
• Sources of Interindividual Variability.

  2021cites this paper
• Minimal contribution of the hepatic uptake transporter OATP1B1 to the inter-individual variability in SN-38 pharmacokinetics in cancer patients without severe renal failure

  2021cites this paper
• In vitro inhibition of human UDP-glucuronosyltransferase (UGT) 1A1 by osimertinib, and prediction of in vivo drug-drug interactions.

  2021cites this paper
• Pharmacogenomic‐Guided Therapy in Colorectal Cancer

  2021cites this paper
• Combination of dabrafenib with irinotecan might trigger off a higher frequency of adverse events by pharmacokinetic interaction

  2021cites this paper
• Clinicopathological features of colorectal cancers in Morocco based on the registry of the National Institute of Oncology in Rabat

  2021cites this paper
• Genomic and epigenomic biomarkers in colorectal cancer: From diagnosis to therapy.

  2021cites this paper
• Pharmacogenomics in the era of next generation sequencing – from byte to bedside

  2021cites this paper
• Pharmacometrics-Based Considerations for the Design of a Pharmacogenomic Clinical Trial Assessing Irinotecan Safety

  2021cites this paper
• Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.

  2021cites this paper
• Predictive and prognostic biomarkers with therapeutic targets in colorectal cancer: A 2021 update on current development, evidence, and recommendation

  2021influential citation
• Development of an LC-MS/MS Method for Measurement of Irinotecan and Its Major Metabolites in Plasma: Technical Considerations.

  2021cites this paper
• Effect of UGT1A1, CYP3A and CES Activities on the Pharmacokinetics of Irinotecan and its Metabolites in Patients with UGT1A1 Gene Polymorphisms

  2021cites this paper
• The Mitochondrial Disruptor Devimistat (CPI-613) Synergizes with Genotoxic Anticancer Drugs in Colorectal Cancer Therapy in a Bim-Dependent Manner

  2021cites this paper
• All You Need to Know About UGT1A1 Genetic Testing for Patients Treated With Irinotecan: A Practitioner-Friendly Guide.

  2021cites this paper
• The rising dominance of microbiology: what to expect in the next 15 years?

  2021cites this paper
• Integration of DNA sequencing with population pharmacokinetics to improve the prediction of irinotecan exposure in cancer patients

  2021cites this paper
• Pharmacogenomics of Anti-Cancer Drugs

  2021cites this paper
• Identification of a UGT1A1*37 Allele in a Korean Patient with Pancreatic Cancer

  2021cites this paper
• The application of “Omics” to accelerate precision medicine in Supportive Care in Cancer

  2021cites this paper
• Population pharmacokinetics of liposomal irinotecan in patients with cancer and exposure–safety analyses in patients with metastatic pancreatic cancer

  2021cites this paper
• Elucidating the role of pharmacogenetics in irinotecan efficacy and adverse events in metastatic colorectal cancer patients

  2021cites this paper
• Different treatment efficacies and side effects of cytotoxic chemotherapy

  2020cites this paper
• Implementation of pharmacogenomic testing in oncology care (PhOCus): study protocol of a pragmatic, randomized clinical trial

  2020cites this paper
• Multicenter, Randomized, Phase III Trial of Neoadjuvant Chemoradiation With Capecitabine and Irinotecan Guided by UGT1A1 Status in Patients With Locally Advanced Rectal Cancer

  2020cites this paper
• Pre-therapeutic UGT1A1 genotyping to reduce the risk of irinotecan-induced severe toxicity: Ready for prime time.

  2020cites this paper
• The Road so Far in Colorectal Cancer Pharmacogenomics: Are We Closer to Individualised Treatment?

  2020cites this paper
• DPYD and UGT1A1 Pharmacogenetic Testing in Patients with Gastrointestinal Malignancies: An Overview of the Evidence and Considerations for Clinical Implementation

  2020cites this paper
• Pharmacogenetic score predicts overall survival, progression-free survival and platinum sensitivity in ovarian cancer.

  2020cites this paper
• Irinotecan or Oxaliplatin: Which is the First Move for the Mate?

  2020cites this paper
• Pharmacogenomics

  2020cites this paper
• ABCB1 Genetic Variants as Predictors of Irinotecan-Induced Severe Gastrointestinal Toxicity in Metastatic Colorectal Cancer Patients

  2020cites this paper
• Pharmacogenetic impact of UGT1A1 polymorphisms on pulmonary neuroendocrine tumours treated with metronomic irinotecan‐based chemotherapy in Chinese populations

  2020cites this paper
• Effect of drug metabolizing enzymes and transporters in Thai colorectal cancer patients treated with irinotecan-based chemotherapy

  2020cites this paper
• Pharmacogenetics for severe adverse drug reactions induced by molecular‐targeted therapy

  2020cites this paper
• SFCE-RAPIRI Phase I Study of Rapamycin Plus Irinotecan: A New Way to Target Intra-Tumor Hypoxia in Pediatric Refractory Cancers

  2020cites this paper
• Human variability in isoform-specific UDP-glucuronosyltransferases: markers of acute and chronic exposure, polymorphisms and uncertainty factors

  2020cites this paper
• Role of Genetic Variations in the Hepatic Handling of Drugs

  2020cites this paper
• Phase 1/2 study of concurrent chemoradiotherapy with weekly irinotecan hydrochloride for advanced/recurrence uterine cancer: A multi-institutional study of Kansai Clinical Oncology Group

  2020cites this paper
• Pharmacogenomics of anticancer drugs: Personalising the choice and dose to manage drug response

  2020cites this paper
• UGT1A1 genotype influences clinical outcome in patients with intermediate-risk acute myeloid leukemia treated with cytarabine-based chemotherapy

  2020cites this paper
• Optimal Sampling Strategies for Irinotecan (CPT-11) and its Active Metabolite (SN-38) in Cancer Patients

  2020cites this paper